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Glycogen synthase kinase-3 (GSK3) is a ubiquitous and pro-
miscuous kinase that has been studied extensively for over
fourdecades.Initialreportsbeginninginthe1970sdescribed
its role in cellular metabolic pathways fundamental to glu-
cose metabolism, but in more recent years the number of
reports describing aberrant GSK3 activity in pathological
conditions has risen dramatically.
Interest in GSK3 in the ﬁeld of Alzheimer’s disease was
ﬁrst sparked in the early 1990s by papers that described
the ability of GSK3 to phosphorylate tau. Excessive tau
phosphorylation is present in Alzheimer’s-disease-aﬀected
brain. These early papers provided new insight to the mech-
anisms that may contribute to tau pathology of Alzheimer’s,
with GSK3 as a potential central ﬁgure. Since then, the
research eﬀort invested into GSK3 in Alzheimer’s disease
has expanded, and mechanistic studies now demonstrate a
functional relationship between not only GSK3 and tau,
but also GSK3 and amyloid-β. Through weight of numbers,
strong evidence now indicates that GSK3 is associated with
the two key pathological features of Alzheimer’s-disease-
aﬀected brain: neuroﬁbrillary tangles and amyloid plaques.
The scope of this special issue is to provide an overview
of the data that implicate GSK3 in Alzheimer’s disease. As
an introduction, the special issue begins with a review of the
regulation of GSK3 activity (M. Medina and F. Wandosell).
This is followed by a report that provides caution by ar-
ticulating the need to demonstrate the bona ﬁde substrates
of GSK3 (C. Sutherland). The role of GSK3 in the brain
and neuronal function is then introduced by two reports.
The ﬁrst is on presynaptic function of GSK3 (K. J. Smillie
and M. A. Cousin) and the second on GSK3 in brain
development and neuronal plasticity (P. Salcedo-Tello et al.).
After this the contribution of GSK3 to neurodegenerative
diseases is described in four reviews. The ﬁrst describes
GSK3 in neurodegenerative diseases in general (P. Lei et al.)
while the following three discuss more speciﬁc aspects of
Alzheimer’s disease, including cell survival mechanisms (M.
A. Mines et al.), inﬂammation (j. Koistinaho et al.), and
tau phosphorylation (D. P. Hanger and W. Nobel). Finally,
the special issue concludes with two reviews on therapeutic
strategies for Alzheimer’s disease that focus on GSK3. The
potential of targeting GSK3 for therapeutic beneﬁt against
oxidative stress is presented (K. Kanninen et al.), followed
by an appraisal of GSK3 inhibitors in the next horizon (A.
Martinez et al.).
Since several GSK3 inhibitors are currently in clinical
trials for treatment of neurological and other disorders, we
feel this special issue is a timely “snapshot” of our current
knowledge of GSK3 function in healthy and diseased brain,
and highlights outstanding issues for future research on this
important brain kinase.
Peter Crouch
Adam Cole
Michael Cousin
Ana Martinez
Katja Kanninen